SCHEMBL25545425

SCHEMBL25545425

COc1c(Cl)cc(-c2nc(N)sc2CC(C)C)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FBP1 P09467 3/20 0.41
▸ HTT P42858 1/20 0.40
▸ ALDH1A1 P00352 4/20 0.38
▸ MAPT P10636 1/20 0.38
▸ TSHR P16473 1/20 0.35
▸ GAA P10253 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ ADORA1 P30542 3/20 0.34
▸ KDM4E B2RXH2 3/20 0.33
▸ PKM P14618 1/20 0.33
▸ RCE1 Q9Y256 1/20 0.33
▸ CYP3A4 P08684 2/20 0.33
▸ CYP1A2 P05177 2/20 0.33
▸ HPGD P15428 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ NPC1 O15118 1/20 0.32
▸ SCN4A P35499 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23782372 0.84 HTT (0.43) FBP1HTTALDH1A1MAPTGAA
SCHEMBL23782509 0.81 ALDH1A1 (0.51) FBP1HTTALDH1A1MAPTGAA
SCHEMBL25545439 0.77 MYC (0.51) FBP1HTTALDH1A1MAPTGAA
SCHEMBL17327675 0.73 ALDH1A1 (0.38) HTTALDH1A1MAPTSMN1; SMN2
SCHEMBL18391844 0.73 ALDH1A1 (0.69) FBP1HTTALDH1A1MAPTGAA
SCHEMBL25545944 0.71 FBP1 (0.44) FBP1ALDH1A1MAPTSMN1; SMN2ADORA1
SCHEMBL25546059 0.71 MPL (0.44) FBP1ALDH1A1MAPTGAASMN1; SMN2
SCHEMBL23792635 0.71 SMN1; SMN2 (0.49) FBP1HTTALDH1A1MAPTGAA
SCHEMBL23782341 0.70 ALDH1A1 (0.49) FBP1HTTALDH1A1MAPTGAA
SCHEMBL30173767 0.70 ALDH1A1 (0.49) FBP1HTTALDH1A1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4392422-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2024-07-03 — — EP disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 — — US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 — — US disclosed
WO-2023028235-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2023-03-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 FBP1 735/4885HTT 1458/4885ALDH1A1 4776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback